Advisor Group Holdings Inc. increases its stake in Hologic, Inc. (NASDAQ: HOLX)


Advisor Group Holdings Inc. increased its stake in Hologic, Inc. (NASDAQ: HOLXGet a rating) by 32.4% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor held 38,475 shares of the medical device supplier after purchasing an additional 9,410 shares during the period. Advisor Group Holdings Inc.’s holdings in Hologic were worth $2,721,000 when it last filed with the SEC.

A number of other institutional investors have also recently changed their positions in the company. BlackRock Inc. increased its stake in Hologic shares by 2.5% in Q4. BlackRock Inc. now owns 21,888,278 shares of the medical equipment supplier valued at $1,675,766,000 after buying an additional 532,526 shares last quarter. State Street Corp increased its stake in Hologic by 3.9% during the fourth quarter. State Street Corp now owns 11,332,073 shares of the medical equipment supplier valued at $867,584,000 after buying an additional 423,495 shares in the last quarter. Geode Capital Management LLC increased its stake in Hologic by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 5,790,351 shares of the medical equipment supplier valued at $442,486,000 after purchasing an additional 398,923 shares in the last quarter. TD Asset Management Inc. increased its stake in Hologic to 78.9% during the 4th quarter. TD Asset Management Inc. now owns 2,656,184 shares of the medical equipment supplier valued at $203,357,000 after purchasing an additional 1,171,229 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Hologic by 18.1% during the 4th quarter. JPMorgan Chase & Co. now owns 2,642,975 shares of the medical equipment supplier valued at $202,346,000 after buying an additional 404,349 shares in the last quarter. Hedge funds and other institutional investors hold 92.70% of the company’s shares.

Insider Activity at Hologic

In related news, insider John Verstreken sold 6,500 shares in a trade dated Tuesday, May 17. The shares were sold at an average price of $78.80, for a total transaction of $512,200.00. Following the sale, the insider now directly owns 64,191 shares of the company, valued at approximately $5,058,250.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via the SEC website. 1.54% of the shares are currently held by insiders.

Wall Street analysts predict growth

A number of equity research analysts have recently commented on the stock. Wells Fargo & Company downgraded Hologic shares from an “overweight” rating to an “equal weight” rating and lowered its price target for the company from $90.00 to $75.00 in a Monday report April 25. BTIG Research downgraded shares of Hologic from a “buy” rating to a “neutral” rating in a Monday, July 18 report. SVB Leerink raised its price target on Hologic shares to $85.00 and gave the stock an “outperform” rating in a Tuesday, May 17 report. Citigroup lowered its price target on Hologic shares from $78.00 to $75.00 in a Thursday, April 28 report. Finally, Morgan Stanley lowered its price target on Hologic shares from $72.00 to $70.00 and set an “equal weight” rating for the company in a Thursday, July 28 report. Seven research analysts gave the stock a hold rating and four gave the company a buy rating. Based on data from MarketBeat.com, Hologic currently has an average rating of “Hold” and an average target price of $76.71.

Hologic stock up 1.3%

NASDAQ: HOLX opened at $72.99 on Friday. The company’s 50-day moving average price is $70.79 and its 200-day moving average price is $72.88. The company has a market capitalization of $18.22 billion, a PE ratio of 12.31, a P/E/G ratio of 0.82 and a beta of 1.05. The company has a debt ratio of 0.57, a current ratio of 3.91 and a quick ratio of 3.32. Hologic, Inc. has a 1-year low of $66.58 and a 1-year high of $81.04.

Hological (NASDAQ: HOLXGet a rating) last reported results on Wednesday, July 27. The medical equipment supplier reported earnings per share of $0.95 for the quarter, beating analysts’ consensus estimate of $0.69 by $0.26. The company posted revenue of $1 billion for the quarter, versus a consensus estimate of $896.71 million. Hologic had a net margin of 28.93% and a return on equity of 37.48%. The company’s revenue decreased by 14.2% compared to the same quarter last year. During the same period of the previous year, the company achieved EPS of $1.33. On average, stock analysts predict Hologic, Inc. will post 5.82 EPS for the current fiscal year.

About Hologic

(Get a rating)

Hologic, Inc develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products for women’s health through early detection and treatment in the United States, Europe, Asia Pacific and the international. It operates through four segments: Diagnostics, Breast Health, Gynecological Surgery and Skeletal Health.

Featured articles

Want to see which other hedge funds hold HOLX? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Hologic, Inc. (NASDAQ: HOLXGet a rating).

Institutional ownership by quarter for Hologic (NASDAQ: HOLX)



Get news and reviews for Hologic Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Hologic and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.